DNAR


Also found in: Acronyms.

DNAR

 
do not attempt resuscitation.

DNAR

abbreviation for do not attempt resuscitation.

DNAR

Do not attempt resuscitation. See DNR.

DNAR

Abbreviation for do not attempt resuscitation.

DNAR

Abbreviation for do not attempt resuscitation.
References in periodicals archive ?
A list of the circumstances under which paramedics can forgo an attempt at resuscitation for adults included the following: (1) a valid DNAR; (2) a valid AHCD with one of the following present at scene: (a) an AHCD with written DNAR instructions, or (b) the agent identified in the AHCD requesting no resuscitation; (3) immediate family member present at scene: (a) with a Living Will or DPAHC on scene requesting no resuscitation, or (b) without said documents at scene, with full agreement of others if present, requesting no resuscitation; or (4) patient in asystole without cardiopulmonary resuscitation (CPR), and the estimated time from collapse to bystander CPR or EMS initiating BLS measures is greater than 10 minutes.
The major changes to the policy include asking family and nursing home staff about DNAR status, respecting a verbal request, and the use of certain limited clinical criteria under which there is no chance of survival.
DNAR is leveraging its deep knowledge of the role that DNA repair pathways play in cancer to create new tools that give physicians unprecedented data-driven insights into which course of treatment will work most effectively for an individual patient.
Ward brings more than two decades of clinical laboratory development, operations and commercialization expertise to DNAR, having successfully developed and directed the creation of several highly profitable clinical laboratories and led commercialization efforts for numerous clinical genetics, genomics and forensics products.
Quan joins DNAR with more than 25 years of management, research, development and securing regulatory approval for biomarkers in the biotechnology and diagnostic industries.
The findings of the researchers on the effect of NQO1*2 on breast cancer survival were highly significant and hold important promise for predicting clinical outcomes for cancer patients," said Daniel Paterson, president and CEO of DNAR, Inc.
Licensing this technology to DNAR provides an exciting opportunity to bring tangible and real-world benefits to patients and their treating physicians," remarked Kari Paukkeri, CEO of Licentia.